Related Experiment Video
Updated: Jun 29, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Retrospective Observational Study to Determine the Epidemiology and Treatment Patterns of Patients with
Magdalena Rosińska1, Roman Dubiański2, Aleksandra Konieczna2
1Computational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Abstract:
Triple-negative breast cancer (TNBC) poses a serious therapeutic challenge due to the occurrence of frequently aggressive, heterogenic, and metastatic tumours. The absence of therapeutic targets for traditional therapies is a hindrance to establishing a standardised therapy for TNBC. There is limited TNBCs epidemiological and real-world data about TNBC treatment regimens in Poland. We retrospectively analysed clinical data from our hospital registry from 2015 and 2020. A total of 8103 individuals with breast cancer were admitted to the MSCI, while 856 (10.6%) were diagnosed with TNBC. Most of the early-stage or locally advanced TNBC individuals had underlying conditions, presented mostly poorly differentiated (G3) stage II tumours and featured a bi-modal age distribution. On average, one-third of all tested TNBCs carried BRCA mutations and its identification impacted surgery preference. We observed a significant increase in the use of systemic therapy among TNBCs, whereas carboplatin and dose-dense regimens showed the most prominent upsurge in the neoadjuvant setting. Moreover, the use of neoadjuvants was positively correlated with less invasive breast and lymph node surgeries. The presented data align with general trends observed in other countries and will contribute to expanding knowledge in the planning of treatment regimens and their outcomes.
Insights
Triple-negative breast cancer (TNBC) treatment in Poland shows increased systemic therapy use, particularly carboplatin and dose-dense regimens. Neoadjuvant therapy correlated with less invasive surgeries for TNBC patients.
Area of Science:
- Oncology
- Clinical Research
- Epidemiology
Background:
- Triple-negative breast cancer (TNBC) presents a significant therapeutic challenge due to its aggressive, heterogeneous, and metastatic nature.
- The lack of specific therapeutic targets hinders standardized treatment protocols for TNBC.
- Limited real-world epidemiological data exists regarding TNBC treatment in Poland.
Purpose of the Study:
- To retrospectively analyze clinical data on TNBC treatment regimens in Poland.
- To identify trends in TNBC patient characteristics and treatment modalities between 2015 and 2020.
- To assess the impact of BRCA mutations and neoadjuvant therapy on surgical outcomes in TNBC.
Main Methods:
- Retrospective analysis of hospital registry data from 2015-2020.
- Inclusion of 856 patients diagnosed with TNBC out of 8103 breast cancer patients.
- Review of patient demographics, tumor characteristics, BRCA mutation status, treatment regimens, and surgical outcomes.
Main Results:
- TNBC patients often presented with comorbidities, poorly differentiated (G3) stage II tumors, and a bimodal age distribution.
- Approximately one-third of tested TNBC cases harbored BRCA mutations, influencing surgical decisions.
- A notable increase in systemic therapy use was observed, with carboplatin and dose-dense regimens showing a significant rise in the neoadjuvant setting.
- Neoadjuvant therapy use was positively associated with less invasive breast and lymph node surgeries.
Conclusions:
- The observed treatment trends in Poland align with international patterns for TNBC management.
- Increased utilization of systemic and neoadjuvant therapies, including carboplatin, is evident.
- Findings support the expansion of knowledge for optimizing TNBC treatment planning and improving patient outcomes.
More Related Videos
07:45Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
